Heart Drug IP Relies On Obvious Aspirin Combo, PTAB Told
Counsel for close to a dozen pharmaceutical companies on Monday urged the Patent Trial and Appeal Board to invalidate a pair of Daiichi Sankyo heart drug patents that have been asserted...To view the full article, register now.
Already a subscriber? Click here to view full article